Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
Awad IA, Polster SP, Carrión-Penagos J, Thompson RE, Cao Y, Stadnik A, Money PL, Fam MD, Koskimäki J, Girard R, Lane K, McBee N, Ziai W, Hao Y, Dodd R, Carlson AP, Camarata PJ, Caron JL, Harrigan MR, Gregson BA, Mendelow AD, Zuccarello M, Hanley DF; MISTIE III Trial Investigators.
Awad IA, et al. Among authors: ziai w.
Neurosurgery. 2019 Jun 1;84(6):1157-1168. doi: 10.1093/neuros/nyz077.
Neurosurgery. 2019.
PMID: 30891610
Free PMC article.
Clinical Trial.